Explore the evolution and clinical application of Conventional Synthetic DMARDs (csDMARDs) in the management of Rheumatoid Arthritis (RA). We break down the historical concept of disease modification, how current rheumatology guidelines view csDMARDs, and why early intervention is critical for controlling inflammation and preventing long-term joint damage.
Key Topics Covered in This Video:
Introduction to DMARDs: Definitions, classification, and their pivotal role in Rheumatoid Arthritis.
Concept Evolution: How the understanding of disease-modifying therapies has shifted over time.
csDMARD Overview: First-line conventional synthetic options (Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, etc.).
Current Clinical Guidelines: Modern treatment paradigms, treat-to-target strategies, and clinical targets for achieving remission.